ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Y-mAbs announces FDA clearance of IND for its Lutetium-177 labelled omburtamab antibody
October 21, 2020Y-mAbs Therapeutics announced that the U.S. Food and Drug Administration has cleared the Company’s Investigational New Drug application for 177Lu-omburtamab-DTPA for the treatment of medulloblastoma, which is the most common type of primary brain cancer.. -
Y-mAbs Secures Commercial Radiolabeling Capacity
July 04, 2019Enters agreement with SpectronRx to produce metastatic central nervous system neuroblastoma treatment, omburtamab. -
MabVax Grants Sublicense to Y-mAbs for Neuroblastoma Vaccine
July 11, 2018MabVax Therapeutics has granted to Y-mAbs Therapeutics an exclusive sublicense to a bi-valent ganglioside based vaccine intended to treat neuroblastoma, a rare pediatric cancer. A third of neuroblastoma patients are diagnosed as infants; and ninety percen
Pharma Sources Insight January 2025
